Fmoc-N-甲基-L-异亮氨酸 | 138775-22-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 异亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Fmoc-N-甲基-L-异亮氨酸
• 中文别名: N-芴甲氧羰基-N-甲基-L-异亮氨酸；芴甲氧羰基-N-甲基-L-异亮氨酸
• 英文名称: N-Fmoc-N-methyl-L-isoleucine
• 英文别名: Fmoc-NMeIle-OH；Fmoc-(Me)Ile-OH；N-methyl-N-Fmoc-L-isoleucine；Fmoc-N-Me-Ile-OH；(2S,3S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylpentanoic acid
• CAS: 138775-22-1
• 化学式: C₂₂H₂₅NO₄
• mdl: MFCD00153389
• 分子量: 367.445
• InChiKey: IQIOLCJHRZWOLS-XOBRGWDASA-N

物化性质

• 熔点：
  177-183 °C
• 沸点：
  537.3±29.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)
• 溶解度：
  溶于水或1%醋酸

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2924 29 70
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Fmoc-N-Me-Ile-OH
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 138775-22-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Chemical characterization : Natural product
Synonyms : Fmoc-N-methyl-L-isoleucine
Formula : C22H25NO4
Molecular Weight : 367,44 g/mol
CAS-No. : 138775-22-1
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone], test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: beige
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

生物活性Fmoc-N-Me-Ile-OH 可用于多肽的合成。

反应信息

• 作为反应物：
  描述：

  Fmoc-N-甲基-L-异亮氨酸 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 以74%的产率得到Fmoc-L-MeIle-F
  参考文献：
  名称：

  通过布朗斯台德酸促进的酰基N-甲基咪唑鎓阳离子的生成来合成N-甲基化的肽。

  摘要：

  牢固的酰胺键形成的发展仍然是N-甲基化肽合成的关键方面。在这项研究中，我们从等量的氨基酸中高收率合成了各种二肽，而没有严重的消旋作用。高反应性的N-甲基咪唑鎓阳离子原位生成以加速酰胺化反应。成功的关键是加入强力的布朗斯台德酸。与常规酰胺化的结果相比，开发的酰胺化使得能够在较短的时间内以较高的产率合成大体积的肽。另外，可以通过使用微流反应器或常规烧瓶来进行酰胺化。天然存在的大体积N-甲基化肽，蝶酰胺I-IV的首次全合成。根据实验结果和理论计算，

  DOI：

  10.1002/anie.202002106
• 作为产物：
  描述：

  N-Fmoc-N-methyl-L-isoleucine benzhydryl ester 在 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 1.0h， 以98%的产率得到Fmoc-N-甲基-L-异亮氨酸
  参考文献：
  名称：

  N-Fmoc-N-甲基-α-氨基酸和N-糖基-N-甲基-α-氨基酸的制备

  摘要：

  亲脂性N -Fmoc- N-甲基-α-氨基酸和N-糖基-N-甲基-α-氨基酸（用于制备N-甲基化肽的有趣结构单元）的合成简便途径是提出了。Nosyl和Fmoc保护的单体都是可及的，因此这些化合物可用于溶液以及固相肽合成中。该方法是基于使用苯甲基来暂时保护N-糖基-α-氨基酸的羧基功能以及随后N的甲基化-重氮基的-nosyl-α-氨基酸二苯甲基酯。苯甲基酯具有几个有益的特征，例如制备简单，对甲基化的稳定性以及在温和条件下的选择性脱保护。整个过程非常有效，因为所采用的条件保持了氨基酸前体的手性完整性，并且该过程不需要对甲基化产物进行色谱纯化。

  DOI：

  10.1007/s00726-008-0221-8

文献信息

• Synthesis and characterization of constrained cyclosporin A derivatives containing a pseudo-proline group
  作者：Luc Patiny、Jean-François Guichou、Michael Keller、Olivier Turpin、Thomas Rückle、Philippe Lhote、Timo M. Buetler、Urs T. Ruegg、Roland M. Wenger、Manfred Mutter

  DOI：10.1016/s0040-4020(03)00770-1

  日期：2003.7

  The chemical synthesis, conformational analysis and receptor binding studies of novel constrained cyclosporin A (CsA) analogues are described. The selective insertion of pseudo-proline (ΨPro) systems featuring different 2-C-substituents at the oxazolidine ring exerts dramatic effects upon the backbone conformation as demonstrated by NMR analysis. It is shown that the insertion of a ΨMeMepro at position

  描述了新型约束环孢菌素A（CsA）类似物的化学合成，构象分析和受体结合研究。NMR分析表明，在恶唑烷环上选择性插入具有不同2-C取代基的伪脯氨酸（ΨPro）系统对骨架构象产生了显着影响。结果表明，在第5位（Thr 5 CsA）插入ΨMeMe pro可以保持与亲环素A以及钙调神经磷酸酶的结合，并显示5-6个顺式酰胺键，其余所有酰胺键反式。用于产生含ΨPro的Cs衍生物的详细合成路线为旨在设计具有选择性活性谱的潜在药理活性化合物的扩展结构-活性关系研究铺平了道路。
• Total synthesis of proposed structure of coibamide A, a highly N- and O-methylated cytotoxic marine cyclodepsipeptide
  作者：Wei He、Hai-Bo Qiu、Yi-Jie Chen、Jie Xi、Zhu-Jun Yao

  DOI：10.1016/j.tetlet.2014.09.047

  日期：2014.10

  Total synthesis of the originally proposed structure of coibamide A, a highly N- and O-methylated cytotoxic marine cyclodepsipeptide, has been accomplished by using a [(4+1)+3+3]-peptide fragment-coupling strategy and careful examination and optimization of the multiple dense N-methylated amide-bond formations. The synthetic sample of the proposed coibamide A could not match the natural product in

  通过使用[（4 + 1）+ 3 + 3]-肽片段偶联策略并仔细检查和完成对coibamide A（一种高度N和O-甲基化的细胞毒性海洋环二肽）最初提出的结构的全合成。优化了多个致密的N-甲基化酰胺键的形成。拟议中的coibamide A的合成样品在1 H和13 C NMR光谱中均无法与天然产物匹配，但发现其对三种测试癌细胞的增殖表现出较低的微摩尔细胞毒性。
• Total Synthesis of the Antifungal Depsipeptide Petriellin A
  作者：Marianne M. Sleebs、Denis Scanlon、John Karas、Rani Maharani、Andrew B. Hughes

  DOI：10.1021/jo201017w

  日期：2011.8.19

  We report the solid-phase total synthesis of the antifungal highly modified cyclic depsipeptide petriellin A. The synthesis confirms earlier reports on the absolute configuration of the natural product. The solid-phase approach resulted in a protected linear precursor, which was cleaved from the solid support prior to cyclization and final deprotection. Use of advanced coupling agents for several hindered

  我们报告了抗真菌的高度修饰的环状depsipeptide petriellin A的固相全合成。该合成证实了关于天然产物的绝对构型的早期报道。固相方法得到受保护的线性前体，其在环化和最终脱保护之前从固体支持物上裂解下来。先进的偶联剂用于几种受阻酰胺是合成的一个特征。天然产物的总产率为5％。
• A Novel Family of Onium Salts Based Upon Isonitroso Meldrum's Acid Proves Useful as Peptide Coupling Reagents
  作者：Ayman El-Faham、Ramon Subirós-Funosas、Fernando Albericio

  DOI：10.1002/ejoc.201000314

  日期：2010.7

  new family of uronium salts (HTMU, HMMU, and HDmPyMU) based on isonitroso Meldrum's acid (HONM) are reported as stand-alone coupling reagents. Amide bond formation with the use of these reagents occurred more quickly than that with other uronium salts as a result of the presence of a neighboring group effect with a cyclic structure. Thus, these novel onium salts were often more effective in the acylation

  据报道，基于异亚硝基 Meldrum 酸 (HONM) 的一系列新的铀盐（HTMU、HMMU 和 HDmPyMU）可用作独立偶联剂。由于存在具有环状结构的相邻基团效应，使用这些试剂形成酰胺键的速度比使用其他脲盐的速度更快。因此，与相关的基于 Oxyma 和苯并三唑的试剂相比，这些新的鎓盐在弱亲核试剂的酰化和光学纯度控制方面通常更有效。在 HONM 衍生物中，HMMU 在减少外消旋化和组装诸如 Aib-ACP 十肽或 Leu-脑啡肽五肽的类似物等要求严格的序列方面表现出最佳性能。此外，还讨论了将 HONM 作为添加剂与碳二亚胺结合使用的范围和限制。
• Structural and mechanistic insights into the inhibition of amyloid-β aggregation by Aβ39-42 fragment derived synthetic peptides
  作者：Akshay Kapadia、Krishna K. Sharma、Indresh Kumar Maurya、Varinder Singh、Madhu Khullar、Rahul Jain

  DOI：10.1016/j.ejmech.2020.113126

  日期：2021.2

  permeability and offered proteolytic stability to the synthetic peptides. Several peptides exhibited promising protection against Aβ aggregation-mediated-neurotoxicity in PC-12 cells at doses ranged between 10 μM and 0.1 μM, further confirmed by the thioflavin-T fluorescence assay. CD study illustrate that these peptides restrict the β-sheet formation, and the non-appearance of Aβ42 fibrillar structures in

  淀粉样-β（Aβ）聚集的抑制是治疗阿尔茨海默氏病（AD）的有前途的方法。合成了基于亲本Aβ肽的Aβ39-42 C末端片段的38个四肽。使用非天然氨基酸的顺序替换/修饰赋予了支架多样性，增强的活性，增强的血脑屏障通透性并为合成肽提供了蛋白水解稳定性。硫黄素-T荧光测定进一步证实了几种肽在PC-12细胞中对Aβ聚集介导的神经毒性具有有希望的保护作用，剂量范围为10μM至0.1μM。CD研究表明，这些肽限制了β-折叠的形成以及Aβ42的不出现电镜中的原纤维结构证实了对Aβ42聚集的抑制。HRMS和ANS荧光光谱分析提供了更多的机理见解。两种选择的前导肽5和16表现出增强的血脑渗透性以及对血清和蛋白水解酶的稳定性。通过计算研究了在Aβ的单体和原纤维单元上的配体-Aβ相互作用的结构见解。前导肽的潜在抑制潜力和短序列为AD的肽衍生疗法的发展提供了新途径。